Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

SHOPPING: If you're ready to take control of your weight loss goals, turn to Get Thin MD for prescription GLP-1 medications ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Government health plans in the U.S. provide significant coverage for new weight-loss drugs, overshadowing private insurers.

Eli Lilly's lineup features two incredibly fast-growing blockbusters: Mounjaro and Zepbound, which treat diabetes and ...

Wegovy's approval by China's NMPA targets individuals with a BMI of 30+ with related health issues; initial supply will be ...